ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

The FDA has approved a supplemental New Drug Application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received 2 or more anti–HER2-based regimens in the metastatic setting, according to a press release issued by the manufacturer Puma Biotechnology, Inc.
Feature:

Coverage from the 2020 Transplantation & Cellular Therapy Meetings Learn More>>

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.